Tang Capital Management Reports 4.21% Stake in Crescent Biopharma, Inc. (CBIO)

Tang Capital Management, LLC, along with Kevin Tang and several affiliated entities (Tang Capital Partners, LP, Tang Capital Partners International, LP, and Tang Capital Partners III, Inc.), filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Crescent Biopharma, Inc. (CBIO). The filing discloses a combined beneficial ownership of 1,160,000 ordinary shares, representing 4.21% of the company based on 27,571,935 shares outstanding as of April 7, 2026. This position reflects an increase from a previous 0% ownership level reported in the provided metadata. Kevin Tang, as the manager of TCM and CEO of the associated entities, shares voting and dispositive power over these shares. The filing indicates that the securities were acquired for investment purposes and not with the intent to influence or change the control of the issuer. Tang Capital Partners IV, Inc. was also listed as a reporting person but reported zero shares owned.